MedTrace Logo

Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

NCT03280342 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-11-01

No results posted yet for this study

Summary

Crossover, randomized, double blind: Q12h dosing in both periods; matching placebo for evening dosing during XR treatment; target dose: 100mg

Conditions

Interventions

DRUG

IR-TPM (Topamax)

XR-TPM (Trokendi XR)

DRUG

XR-TPM (Trokendi XR)

XR-TPM (Trokendi XR)

Sponsors & Collaborators

Principal Investigators

  • Susan Marino, PhD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2018-08-20
Completion
2018-09-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03280342 on ClinicalTrials.gov